Eight years af­ter a land­mark buy­out, Sanofi agrees to pay ag­griev­ed Gen­zyme share­hold­ers $315M to set­tle foot-drag­ging claims

Sanofi’s $20 bil­lion deal to buy Gen­zyme in ear­ly 2011 qual­i­fies as one of the smartest M&A pacts in in­dus­try his­to­ry, net­ting a block­buster MS drug fran­chise that still de­liv­ers bil­lions to the phar­ma gi­ant.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.